Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq

Classical Hodgkin lymphoma (CHL) is characterized by a complex tumor microenvironment (TME) that supports disease progression. Although immune cell recruitment by Hodgkin and Reed-Sternberg (HRS) cells is well documented, the role of nonmalignant B cells in relapse remains unclear. Using single-cell RNA sequencing (scRNA-seq) on paired diagnostic and relapsed CHL samples, we identified distinct shifts in B-cell populations, particularly an enrichment of naïve B cells and a reduction of memory B cells in early-relapse CHL compared to late-relapse and newly diagnosed CHL. The enrichment of naïve B cells in early relapse biopsies was confirmed in independent validation cohorts using scRNA-seq and immunohistochemistry. Notably, naïve B cells in early-relapse samples exhibited high expression of LGALS9, an immunosuppressive gene encoding galectin-9, which binds to HAVCR2 (T-cell immunoglobulin and mucin domain-containing protein 3 [TIM-3]) on regulatory T cells (Tregs). Cell-cell interaction analysis revealed the importance of interactions between LGALS9+ naïve B cells and HAVCR2+ Tregs in the early-relapse setting. Spatial analysis by imaging mass cytometry confirmed close proximity of galectin-9-positive naïve B cells with TIM-3+ CD4+ T cells and HRS cells, pointing to their role in shaping an immunosuppressive niche. Our findings highlight a previously unrecognized population of galectin-9-positive naïve B cells with immunoregulatory potential in early-relapse CHL and provide new insights into the spatial and transcriptional architecture of the relapsed TME in CHL.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2025-09-09
DOI
https://doi.org/10.1182/bloodadvances.2025017107
Citations
1
Primary Topic
Galectins and Cancer Biology
Type
article
Field-Weighted Citation Impact
0.80

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq

Shinya Rai, Aixiang Jiang, Kerry J. Savage, Stacy Hung et al.
1 citations
Blood Advances
Galectins and Cancer Biology
0.80
article

Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq

Shinya Rai, Aixiang Jiang, Kerry J. Savage, Stacy Hung, David W. Scott, Christian Steidl, Adèle Telenius, Luke O’Brien, Alexander M. Xu, Akil Abid Merchant, Tomohiro Aoki, Jan Delabie, Lauren C. Chong, Yifan Yin
article en
1 citations

Abstract

Classical Hodgkin lymphoma (CHL) is characterized by a complex tumor microenvironment (TME) that supports disease progression. Although immune cell recruitment by Hodgkin and Reed-Sternberg (HRS) cells is well documented, the role of nonmalignant B cells in relapse remains unclear. Using single-cell RNA sequencing (scRNA-seq) on paired diagnostic and relapsed CHL samples, we identified distinct shifts in B-cell populations, particularly an enrichment of naïve B cells and a reduction of memory B cells in early-relapse CHL compared to late-relapse and newly diagnosed CHL. The enrichment of naïve B cells in early relapse biopsies was confirmed in independent validation cohorts using scRNA-seq and immunohistochemistry. Notably, naïve B cells in early-relapse samples exhibited high expression of LGALS9, an immunosuppressive gene encoding galectin-9, which binds to HAVCR2 (T-cell immunoglobulin and mucin domain-containing protein 3 [TIM-3]) on regulatory T cells (Tregs). Cell-cell interaction analysis revealed the importance of interactions between LGALS9+ naïve B cells and HAVCR2+ Tregs in the early-relapse setting. Spatial analysis by imaging mass cytometry confirmed close proximity of galectin-9-positive naïve B cells with TIM-3+ CD4+ T cells and HRS cells, pointing to their role in shaping an immunosuppressive niche. Our findings highlight a previously unrecognized population of galectin-9-positive naïve B cells with immunoregulatory potential in early-relapse CHL and provide new insights into the spatial and transcriptional architecture of the relapsed TME in CHL.

Blood AdvancesVol. 10(1)
Cedars-Sinai Medical Center (US), BC Cancer Agency (CA), University Health Network (CA), University of British Columbia (CA), University of Toronto (CA), Spinal Cord Injury BC (CA), Princess Margaret Cancer Centre (CA), Kindai University Hospital (JP), University of Maryland, College Park (US), Kindai University (JP)
AstraZeneca, Uehara Memorial Foundation, Genome Canada, Regeneron Pharmaceuticals, Veracyte, Genome British Columbia, Provincial Health Services Authority, Eisai, Terry Fox Research Institute, Genentech, Canadian Institutes of Health Research
Openalex Percentile: Top 24%
Galectins and Cancer Biology
0.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.